Onkologija
Liječenje trombocitopenije
Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support. (otvara se novi prozor)
Izvor: Br J Haematol 2013;161(5):738-40.
Indeks: PubMed 23480574
DOI: 10.1111/bjh.12284
https://www.ncbi.nlm.nih.gov/pubmed/23480574 (otvara se novi prozor)
A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. (otvara se novi prozor)
Izvor: Haematologica 2021;106(4):1148-57.
Indeks: PubMed 32499239
DOI: 10.3324/haematol.2020.251900
https://www.ncbi.nlm.nih.gov/pubmed/32499239 (otvara se novi prozor)
The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. (otvara se novi prozor)
Izvor: Cancer 2008;113(6):1338-43.
Indeks: PubMed 18629842
DOI: 10.1002/cncr.23718
https://www.ncbi.nlm.nih.gov/pubmed/18629842 (otvara se novi prozor)
Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia. (otvara se novi prozor)
Izvor: Transfusion 2012;52(4):739-41.
Indeks: PubMed 22082044
DOI: 10.1111/j.1537-2995.2011.03382.x
https://www.ncbi.nlm.nih.gov/pubmed/22082044 (otvara se novi prozor)
The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. (otvara se novi prozor)
Izvor: Leuk Lymphoma 2007;48(1):9-15.
Indeks: PubMed 17325843
DOI: 10.1080/10428190600909115
https://www.ncbi.nlm.nih.gov/pubmed/17325843 (otvara se novi prozor)
Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. (otvara se novi prozor)
Izvor: BMC Cancer 2013;13:121.
Indeks: PubMed 23497336
DOI: 10.1186/1471-2407-13-121
https://www.ncbi.nlm.nih.gov/pubmed/23497336 (otvara se novi prozor)
Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. (otvara se novi prozor)
Izvor: Pathol Oncol Res 2011;17(1):141-3.
Indeks: PubMed 20628840
DOI: 10.1007/s12253-010-9276-4
https://www.ncbi.nlm.nih.gov/pubmed/20628840 (otvara se novi prozor)
Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient. (otvara se novi prozor)
Izvor: J Neurooncol 2012;106(2):427-9.
Indeks: PubMed 21833801
DOI: 10.1007/s11060-011-0675-5
https://www.ncbi.nlm.nih.gov/pubmed/21833801 (otvara se novi prozor)
Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. (otvara se novi prozor)
Izvor: Lancet 2003;361(9354):275-80.
Indeks: PubMed 12559860
https://www.ncbi.nlm.nih.gov/pubmed/12559860 (otvara se novi prozor)
Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (otvara se novi prozor)
Izvor: J Clin Oncol 2015;33(15):1674-9.
Indeks: PubMed 25870085
DOI: 10.1200/JCO.2014.57.9912
https://www.ncbi.nlm.nih.gov/pubmed/25870085 (otvara se novi prozor)
Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors. (otvara se novi prozor)
Izvor: Platelets. 2022 3;33(7):1024-1030.
Indeks: PubMed 35040375
DOI: 10.1080/09537104.2022.2026910
https://pubmed.ncbi.nlm.nih.gov/35040375/ (otvara se novi prozor)
Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. (otvara se novi prozor)
Izvor: Cancer 2014;120(12):1838-46.
Indeks: PubMed 24706489
DOI: 10.1002/cncr.28663
https://www.ncbi.nlm.nih.gov/pubmed/24706489 (otvara se novi prozor)
A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. (otvara se novi prozor)
Izvor: Leuk Lymphoma 2013;54(2):321-8.
Indeks: PubMed 22906162
DOI: 10.3109/10428194.2012.713477
https://www.ncbi.nlm.nih.gov/pubmed/22906162 (otvara se novi prozor)
Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. (otvara se novi prozor)
Izvor: Platelets 2012;23(6):423-9.
Indeks: PubMed 22185370
DOI: 10.3109/09537104.2011.634931
https://www.ncbi.nlm.nih.gov/pubmed/22185370 (otvara se novi prozor)
Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial. (otvara se novi prozor)
Izvor: Ann Hematol 2015;94(1):117-28.
Indeks: PubMed 25069650
DOI: 10.1007/s00277-014-2158-1
https://www.ncbi.nlm.nih.gov/pubmed/25069650 (otvara se novi prozor)
The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma. (otvara se novi prozor)
Izvor: J Hematol Oncol 2015;8:37.
Indeks: PubMed 25886818
DOI: 10.1186/s13045-015-0136-2
https://www.ncbi.nlm.nih.gov/pubmed/25886818 (otvara se novi prozor)
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. (otvara se novi prozor)
Izvor: J Clin Oncol 2010;28(3):437-44.
Indeks: PubMed 20008626
DOI: 10.1200/JCO.2009.24.7999
https://www.ncbi.nlm.nih.gov/pubmed/20008626 (otvara se novi prozor)
The use of simple patient blood management strategies as an alternative to platelet and red cell transfusion in autologous stem cell transplant. (otvara se novi prozor)
Izvor: Blood 2013;122(21):2140.
https://www.bloodjournal.org/content/122/21/2140 (otvara se novi prozor)
The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. (otvara se novi prozor)
Izvor: Blood 1999;93(10):3286-93.
Indeks: PubMed 10233880
https://www.ncbi.nlm.nih.gov/pubmed/10233880 (otvara se novi prozor)
A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia. (otvara se novi prozor)
Izvor: Am J Hematol 2018;93(4):E86-E88.
Indeks: PubMed 29274130
DOI: 10.1002/ajh.25022
https://www.ncbi.nlm.nih.gov/pubmed/29274130 (otvara se novi prozor)
Pharmacological therapies to minimise platelet transfusion. (otvara se novi prozor)
Izvor: Transfus Sci 2000;22(3):149-53.
Indeks: PubMed 10831916
https://www.ncbi.nlm.nih.gov/pubmed/10831916 (otvara se novi prozor)
Romiplostim for management of chemotherapy-induced thrombocytopenia. (otvara se novi prozor)
Izvor: Support Care Cancer 2014;22(5):1217-22.
Indeks: PubMed 24414994
DOI: 10.1007/s00520-013-2074-2
https://www.ncbi.nlm.nih.gov/pubmed/24414994 (otvara se novi prozor)
Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. (otvara se novi prozor)
Izvor: Expert Opin Drug Metab Toxicol 2013;9(12):1667-75.
Indeks: PubMed 24215532
DOI: 10.1517/17425255.2013.858119
https://www.ncbi.nlm.nih.gov/pubmed/24215532 (otvara se novi prozor)
High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (otvara se novi prozor)
Izvor: Leuk Lymphoma. 2019;60(9):2324-7.
Indeks: PubMed 30773115
DOI: 10.1080/10428194.2019.1577414
https://www.ncbi.nlm.nih.gov/pubmed/30773115 (otvara se novi prozor)
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. (otvara se novi prozor)
Izvor: Lancet Haematol 2015;2(10):e417-26.
Indeks: PubMed 26686043
https://www.ncbi.nlm.nih.gov/pubmed/26686043 (otvara se novi prozor)
Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation. (otvara se novi prozor)
Izvor: Am J Blood Res 2013;3(3):260-4.
Indeks: PubMed 23997988
https://www.ncbi.nlm.nih.gov/pubmed/23997988 (otvara se novi prozor)
Safety and efficacy of eltrombopag in post-hematopoietic stem cell transplantation (HSCT) thrombocytopenia. (otvara se novi prozor)
Izvor: Indian J Hematol Blood Transfus 2015;31(4):413-5.
Indeks: PubMed 26306064
DOI: 10.1007/s12288-014-0491-0
https://www.ncbi.nlm.nih.gov/pubmed/26306064 (otvara se novi prozor)
Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. (otvara se novi prozor)
Izvor: Blood 2010;116(12):2127-33.
Indeks: PubMed 20530792
DOI: 10.1182/blood-2010-03-276691
https://www.ncbi.nlm.nih.gov/pubmed/20530792 (otvara se novi prozor)
Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. (otvara se novi prozor)
Izvor: Blood 2012;120(2):386-94.
Indeks: PubMed 22627766
DOI: 10.1182/blood-2011-12-399667
https://www.ncbi.nlm.nih.gov/pubmed/22627766 (otvara se novi prozor)
Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. (otvara se novi prozor)
Izvor: Cancer 2011;117(5):992-1000.
Indeks: PubMed 20945323
DOI: 10.1002/cncr.25545
https://www.ncbi.nlm.nih.gov/pubmed/20945323 (otvara se novi prozor)
Romiplostim treatment of chemotherapy-induced thrombocytopenia. (otvara se novi prozor)
Izvor: J Clin Oncol 2019;37(31):2892-8.
Indeks: PubMed 31545663
DOI: 10.1200/JCO.18.01931
https://www.ncbi.nlm.nih.gov/pubmed/31545663 (otvara se novi prozor)
Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. (otvara se novi prozor)
Izvor: Blood 2000;95(9):2983-9.
Indeks: PubMed 10779449
https://www.ncbi.nlm.nih.gov/pubmed/10779449 (otvara se novi prozor)
A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. (otvara se novi prozor)
Izvor: Eur J Haematol 2014;93(5):439-45.
Indeks: PubMed 24853277
DOI: 10.1111/ejh.12383
https://www.ncbi.nlm.nih.gov/pubmed/24853277 (otvara se novi prozor)
Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. (otvara se novi prozor)
Izvor: Biol Blood Marrow Transplant 2016;22(5):919-24.
Indeks: PubMed 26785333
DOI: 10.1016/j.bbmt.2016.01.018
https://www.ncbi.nlm.nih.gov/pubmed/26785333 (otvara se novi prozor)
Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. (otvara se novi prozor)
Izvor: Ann Oncol 2005;16(1):139-45.
Indeks: PubMed 15598951
DOI: 10.1093/annonc/mdi007
https://www.ncbi.nlm.nih.gov/pubmed/15598951 (otvara se novi prozor)
A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. (otvara se novi prozor)
Izvor: J Hematol Oncol 2012;5:71.
Indeks: PubMed 23190430
DOI: 10.1186/1756-8722-5-71
https://www.ncbi.nlm.nih.gov/pubmed/23190430 (otvara se novi prozor)
Romiplostim for chemotherapy-induced thrombocytopenia: efficacy and safety of extended use. (otvara se novi prozor)
Izvor: Res Pract Thromb Haemost. 2022;6(3):e12701.
Indeks: PubMed 35582038
DOI: 10.1002/rth2.12701
https://pubmed.ncbi.nlm.nih.gov/35582038/ (otvara se novi prozor)
Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. (otvara se novi prozor)
Izvor: Blood 2009;114(18):3899-908.
Indeks: PubMed 19710504
DOI: 10.1182/blood-2009-04-219493
https://www.ncbi.nlm.nih.gov/pubmed/19710504 (otvara se novi prozor)